TJ DaRenTang USD T14

USD 2.61 -0.38% -0.01 Updated 30 Oct 2026, 17:16 SGT

Financials

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025

Open annual report

Explore the statements

33 tables

Group / Company balance sheets — FY2025 source

38 metrics

Units appear below each metric. Scroll to compare years

Group / Company balance sheets — FY2025 source from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2025Group2024Group2025Company2024Company Source
Non-Current Assets
Property, plant and equipmentChinese yuan thousands 1,133,9991,386,801914,2991,041,001 PDF p. 76
Investment propertiesChinese yuan thousands 110,36711,279110,36711,279 PDF p. 76
Right-of-use assetsChinese yuan thousands 7,5486,6451,861– PDF p. 76
Land use rightsChinese yuan thousands 224,507243,681191,776197,727 PDF p. 76
Intangible assetsChinese yuan thousands 86,639106,23578,96649,723 PDF p. 76
SubsidiariesChinese yuan thousands ––933,4041,048,534 PDF p. 76
AssociatesChinese yuan thousands 1,165,6621,293,5281,165,6621,293,528 PDF p. 76
Deferred tax assetsChinese yuan thousands 341,007314,400315,253287,789 PDF p. 76
Other financial assetsChinese yuan thousands 1,427,139771,9611,273,018578,146 PDF p. 76
Other assetsChinese yuan thousands 38,34726,03130,76224,078 PDF p. 76
SubtotalChinese yuan thousands 4,535,2154,160,5615,015,3684,531,805 PDF p. 76
Current Assets
InventoriesChinese yuan thousands 1,132,9681,285,6871,026,1471,154,187 PDF p. 76
Trade and other receivablesChinese yuan thousands 1,603,6941,324,8891,456,1561,146,740 PDF p. 76
Other financial assetsChinese yuan thousands 3,316,0081,000,0723,191,129968,039 PDF p. 76
Other assetsChinese yuan thousands 85,42252,98166,13336,774 PDF p. 76
Cash and cash equivalentsChinese yuan thousands 1,016,4272,944,433765,3392,736,763 PDF p. 76
SubtotalChinese yuan thousands 7,154,5196,608,0626,504,9046,042,503 PDF p. 76
Total assetsChinese yuan thousands 11,689,73410,768,62311,520,27210,574,308 PDF p. 76
EQUITY
Capital and Reserves Share capitalChinese yuan thousands 770,094770,094770,094770,094 PDF p. 76 Label p. 76
Share premiumChinese yuan thousands 1,206,9301,206,9301,206,9301,206,930 PDF p. 76
Retained earningsChinese yuan thousands 5,002,3465,743,7764,681,5665,531,353 PDF p. 76
Other reservesChinese yuan thousands 120,129122,794534,778537,637 PDF p. 76
Equity attributable to owners
Equity attributable to owners of the companyChinese yuan thousands 7,099,4997,843,5947,193,3688,046,014 PDF p. 76 Label p. 76
Non-controlling interestsChinese yuan thousands 4466,344–– PDF p. 76
Total equityChinese yuan thousands 7,099,9457,849,9387,193,3688,046,014 PDF p. 76
Non-Current Liabilities
Deferred tax liabilitiesChinese yuan thousands 2766,038–– PDF p. 76
Trade and other payablesChinese yuan thousands 2,3993,5392,2593,361 PDF p. 76
Lease liabilitiesChinese yuan thousands 4,6585,603510– PDF p. 76
Other liabilitiesChinese yuan thousands 76,01885,67163,06760,806 PDF p. 76
SubtotalChinese yuan thousands 83,351100,85165,83664,167 PDF p. 76
Current Liabilities
Income tax payableChinese yuan thousands 29,216297,56925,192281,485 PDF p. 76
Trade and other payablesChinese yuan thousands 4,212,7302,309,8773,991,5471,983,867 PDF p. 76
Lease liabilitiesChinese yuan thousands 3,1251,3291,190– PDF p. 76
Other financial liabilitiesChinese yuan thousands 57,90321,65348,86419,653 PDF p. 76
Other liabilitiesChinese yuan thousands 203,464187,406194,275179,122 PDF p. 76
SubtotalChinese yuan thousands 4,506,4382,817,8344,261,0682,464,127 PDF p. 76
Total liabilitiesChinese yuan thousands 4,589,7892,918,6854,326,9042,528,294 PDF p. 76
Total equity and liabilitiesChinese yuan thousands 11,689,73410,768,62311,520,27210,574,308 PDF p. 76
Definitions & sources

Consolidated profit / comprehensive income — FY2025 source

26 metrics

Units appear below each metric. Scroll to compare years

Consolidated profit / comprehensive income — FY2025 source from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2025Group2024Group Source
Consolidated profit / comprehensive income — FY2025 source
RevenueChinese yuan thousands 4,917,3367,306,736 PDF p. 77
Cost of salesChinese yuan thousands (1,357,623)(3,861,821) PDF p. 77
Gross ProfitChinese yuan thousands 3,559,7133,444,915 PDF p. 77
Interest incomeChinese yuan thousands 41,83828,777 PDF p. 77
Dividend incomeChinese yuan thousands 24280 PDF p. 77
Other income and gainsChinese yuan thousands 1,650,6331,790,021 PDF p. 77
Marketing and distribution expensesChinese yuan thousands (2,025,611)(1,999,975) PDF p. 77
Research and development expensesChinese yuan thousands (189,808)(162,378) PDF p. 77
Administrative expensesChinese yuan thousands (402,602)(477,298) PDF p. 77
Finance costsChinese yuan thousands (968)(30,638) PDF p. 77
Other lossesChinese yuan thousands (164,300)(182,929) PDF p. 77
Share of results of equity-accounted associates, net of taxChinese yuan thousands 18,315168,208 PDF p. 77
Profit before taxChinese yuan thousands 2,487,4522,578,783 PDF p. 77
Tax expenseChinese yuan thousands (376,702)(363,564) PDF p. 77
Profit for the yearChinese yuan thousands 2,110,7502,215,219 PDF p. 77
Items that may be reclassified subsequently to profit or loss:
Other reserve reclassified to profit or loss upon disposal of equity interests in an associate, net of taxChinese yuan thousands (600)(650) PDF p. 77 Label p. 77
Items that will not be reclassified subsequently to profit or loss:
Change in fair value of equity investments measured at FVOCI, net of taxChinese yuan thousands (78)(233) PDF p. 77 Label p. 77
Share of other comprehensive loss from equity-accounted associates, net of taxChinese yuan thousands (2,181)(6,523) PDF p. 77 Label p. 77
Other comprehensive income for the yearChinese yuan thousands (2,859)(7,406) PDF p. 77
Total comprehensive income for the yearChinese yuan thousands 2,107,8912,207,813 PDF p. 77
Profit for the year attributable to: Owners of the CompanyChinese yuan thousands 2,131,0222,229,335 PDF p. 77 Label p. 77
Non-controlling interestsChinese yuan thousands (20,272)(14,116) PDF p. 77
Profit for the yearChinese yuan thousands 2,110,7502,215,219 PDF p. 77
Total comprehensive income attributable to:
Owners of the CompanyChinese yuan thousands 2,128,1632,221,929 PDF p. 77
Non-controlling interestsChinese yuan thousands (20,272)(14,116) PDF p. 77
Total comprehensive income for the yearChinese yuan thousands 2,107,8912,207,813 PDF p. 77
Definitions & sources

Basic / diluted EPS — FY2025 source

1 metrics

Units appear below each metric. Scroll to compare years

Basic / diluted EPS — FY2025 source from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2025Group2024Group Source
Total comprehensive income attributable to:
Profit per share attributable to owners of the Company Basic and diluted (RMB per share)Chinese yuan per share 2.772.90 PDF p. 77 Label p. 77
Definitions & sources

Group equity movements — FY2025 source — ending2025

11 metrics

Units appear below each metric. Scroll to compare years

Group equity movements — FY2025 source — ending2025 from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2025Group — Share capital2025Group — Share premium2025Group — Other reserves2025Group — Retained earnings2025Group — Equity attributable to owners2025Group — Non-controlling interests2025Group — Total equity Source
Group equity movements — FY2025 source
At 1 January 2025Chinese yuan thousands 770,0941,206,930122,7945,743,7767,843,5946,3447,849,938 PDF p. 78
Profit for the yearChinese yuan thousands –––2,131,0222,131,022(20,272)2,110,750 PDF p. 78
Other reserve reclassified to profit or loss upon disposal of equity interests in an associate, net of taxChinese yuan thousands ––(600)–(600)–(600) PDF p. 78 Label p. 78
Change in fair value of equity investments measured at FVOCI, net of taxChinese yuan thousands ––(78)–(78)–(78) PDF p. 78 Label p. 78
Share of other comprehensive income from equity-accounted associates, net of taxChinese yuan thousands ––(2,181)–(2,181)–(2,181) PDF p. 78 Label p. 78
Total other comprehensive lossChinese yuan thousands ––(2,859)–(2,859)–(2,859) PDF p. 78
Total comprehensive (loss)/ incomeChinese yuan thousands ––(2,859)2,131,0222,128,163(20,272)2,107,891 PDF p. 78 Label p. 78
Contributions by and distributions
Dividends (Note 32)Chinese yuan thousands –––(2,872,452)(2,872,452)–(2,872,452) PDF p. 78
Liquidation of subsidiary with non-controlling interests (Note 9(b))Chinese yuan thousands ––194–19414,37414,568 PDF p. 78 Label p. 78
Total transactions with ownersChinese yuan thousands ––194(2,872,452)(2,872,258)14,374(2,857,884) PDF p. 78
At 31 December 2025Chinese yuan thousands 770,0941,206,930120,1295,002,3467,099,4994467,099,945 PDF p. 78
Definitions & sources

Group equity movements — FY2025 source — ending2024

14 metrics

Units appear below each metric. Scroll to compare years

Group equity movements — FY2025 source — ending2024 from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2024Group — Share capital2024Group — Share premium2024Group — Other reserves2024Group — Retained earnings2024Group — Equity attributable to owners2024Group — Non-controlling interests2024Group — Total equity Source
Contributions by and distributions
At 1 January 2024Chinese yuan thousands 770,1581,207,326130,2244,500,0206,607,72844,5466,652,274 PDF p. 78
Profit for the yearChinese yuan thousands –––2,229,3352,229,335(14,116)2,215,219 PDF p. 78
Other reserve reclassified to profit or loss upon partial disposal of equity interests in an associate, net of taxChinese yuan thousands ––(650)–(650)–(650) PDF p. 78 Label p. 78
Change in fair value of equity investments measured at FVOCI, net of taxChinese yuan thousands ––(233)–(233)–(233) PDF p. 78 Label p. 78
Share of other comprehensive income from equity-accounted associates, net of taxChinese yuan thousands ––(6,523)–(6,523)–(6,523) PDF p. 78 Label p. 78
Total other comprehensive incomeChinese yuan thousands ––(7,406)–(7,406)–(7,406) PDF p. 78
Total comprehensive incomeChinese yuan thousands ––(7,406)2,229,3352,221,929(14,116)2,207,813 PDF p. 78
Dividends (Note 32)Chinese yuan thousands –––(985,803)(985,803)–(985,803) PDF p. 78
Dividends paid to non-controlling interests (Note 32)Chinese yuan thousands –––––(4,980)(4,980) PDF p. 78 Label p. 78
Disposal of subsidiaries with non-controlling interests (Note 9(a))Chinese yuan thousands –––––(19,106)(19,106) PDF p. 78 Label p. 78
Net reversal of share-based payments (Note 17)Chinese yuan thousands ––(24)–(24)–(24) PDF p. 78 Label p. 78
Repurchase and cancellation of Restricted A-SharesChinese yuan thousands (64)(396)–224(236)–(236) PDF p. 78 Label p. 78
Total transactions with ownersChinese yuan thousands (64)(396)(24)(985,579)(986,063)(24,086)(1,010,149) PDF p. 78
At 31 December 2024Chinese yuan thousands 770,0941,206,930122,7945,743,7767,843,5946,3447,849,938 PDF p. 78
Definitions & sources

Company equity movements — FY2025 source — ending2025

9 metrics

Units appear below each metric. Scroll to compare years

Company equity movements — FY2025 source — ending2025 from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2025Company — Share capital2025Company — Share premium2025Company — Other reserves2025Company — Retained earnings2025Company — Total equity Source
Company equity movements — FY2025 source
At 1 January 2025Chinese yuan thousands 770,0941,206,930537,6375,531,3538,046,014 PDF p. 79
Profit for the yearChinese yuan thousands –––2,022,6652,022,665 PDF p. 79
Other reserve reclassified to profit or loss upon partial disposal of associate, net of taxChinese yuan thousands ––(600)–(600) PDF p. 79 Label p. 79
Change in fair value of equity investments measured at FVOCI, net of taxChinese yuan thousands ––(78)–(78) PDF p. 79 Label p. 79
Share of other comprehensive income from equity-accounted associates, net of taxChinese yuan thousands ––(2,181)–(2,181) PDF p. 79 Label p. 79
Total comprehensive incomeChinese yuan thousands ––(2,859)2,022,6652,019,806 PDF p. 79
Contributions by and distributions
Dividends (Note 32)Chinese yuan thousands –––(2,872,452)(2,872,452) PDF p. 79
Total transactions with ownersChinese yuan thousands –––(2,872,452)(2,872,452) PDF p. 79
At 31 December 2025Chinese yuan thousands 770,0941,206,930534,7784,681,5667,193,368 PDF p. 79
Definitions & sources

Company equity movements — FY2025 source — ending2024

11 metrics

Units appear below each metric. Scroll to compare years

Company equity movements — FY2025 source — ending2024 from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2024Company — Share capital2024Company — Share premium2024Company — Other reserves2024Company — Retained earnings2024Company — Total equity Source
Contributions by and distributions
At 1 January 2024Chinese yuan thousands 770,1581,207,326545,0674,456,4606,979,011 PDF p. 79
Profit for the yearChinese yuan thousands –––2,060,4722,060,472 PDF p. 79
Other reserve reclassified to profit or loss upon partial disposal of associate, net of taxChinese yuan thousands ––(650)(650) PDF p. 79 Label p. 79
Change in fair value of equity investments measured at FVOCI, net of taxChinese yuan thousands ––(233)–(233) PDF p. 79 Label p. 79
Share of other comprehensive income from equity-accounted associates, net of taxChinese yuan thousands ––(6,523)–(6,523) PDF p. 79 Label p. 79
Total comprehensive incomeChinese yuan thousands ––(7,406)2,060,4722,053,066 PDF p. 79
Dividends (Note 32)Chinese yuan thousands –––(985,803)(985,803) PDF p. 79
Net reversal of share-based payments (Note 17)Chinese yuan thousands ––(24)–(24) PDF p. 79 Label p. 79
Repurchase and cancellation of Restricted A-SharesChinese yuan thousands (64)(396)–224(236) PDF p. 79 Label p. 79
Total transactions with ownersChinese yuan thousands (64)(396)(24)(985,579)(986,063) PDF p. 79
At 31 December 2024Chinese yuan thousands 770,0941,206,930537,6375,531,3538,046,014 PDF p. 79
Definitions & sources

Consolidated cash flows — FY2025 source

44 metrics

Units appear below each metric. Scroll to compare years

Consolidated cash flows — FY2025 source from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2025Group2024Group Source
Cash flows from operating activities
Profit before taxChinese yuan thousands 2,487,4522,578,783 PDF p. 80
Adjustments for:
Bargain purchase gain on acquisition of additional equity interests in an associateChinese yuan thousands –(5,852) PDF p. 80 Label p. 80
Depreciation and amortisation of property, plant and equipment, investment properties, right-of-use assets, land use rights, intangible assets and other non-current assetsChinese yuan thousands 125,037128,212 PDF p. 80 Label p. 80
Dividend incomeChinese yuan thousands (242)(80) PDF p. 80
ECL allowance for trade and other receivablesChinese yuan thousands 8,32050,096 PDF p. 80
Elimination of unrealised profits arising from transactions with associatesChinese yuan thousands 40,281– PDF p. 80 Label p. 80
Gain on disposal of an associateChinese yuan thousands (1,542,929)(1,709,262) PDF p. 80
Gain on disposal of land use rightsChinese yuan thousands (3,487)– PDF p. 80
Gain on lease modificationChinese yuan thousands (176)– PDF p. 80
Gain on liquidation of a subsidiaryChinese yuan thousands (17,374)– PDF p. 80
Impairment of goodwillChinese yuan thousands 12,30153,610 PDF p. 80
Impairment of property, plant and equipmentChinese yuan thousands 75,22360,155 PDF p. 80
Impairment of land use rightsChinese yuan thousands 3,276– PDF p. 80
Impairment of intangible assetsChinese yuan thousands 26,711– PDF p. 80
Interest incomeChinese yuan thousands (41,838)(28,777) PDF p. 80
Interest expenseChinese yuan thousands 96830,638 PDF p. 80
Investment income on debts instruments at amortised costChinese yuan thousands (66,868)(30,237) PDF p. 80
Loss/(gain) on disposal of property, plant and equipmentChinese yuan thousands 832(73) PDF p. 80
Net reversal of share-based paymentsChinese yuan thousands –(24) PDF p. 80
Property, plant and equipment written offChinese yuan thousands 196– PDF p. 80
Share of results of equity-accounted associates, net of taxChinese yuan thousands (18,315)(168,208) PDF p. 80
Write-down of inventories to net realisable valueChinese yuan thousands 34,98817,555 PDF p. 80
Operating profit before working capital changesChinese yuan thousands 1,124,356976,536 PDF p. 80
Changes in working capital:
– InventoriesChinese yuan thousands 117,731(30,958) PDF p. 80
– Trade and other receivablesChinese yuan thousands (227,915)(26,241) PDF p. 80
– Other assetsChinese yuan thousands (54,134)52,486 PDF p. 80
– Trade and other payablesChinese yuan thousands 131,669(19,459) PDF p. 80
– Cash restricted in useChinese yuan thousands –127,814 PDF p. 80
– Other liabilitiesChinese yuan thousands 6,40517,689 PDF p. 80
Cash generated from operationsChinese yuan thousands 1,098,1121,097,867 PDF p. 80
Tax paidChinese yuan thousands (678,881)(201,972) PDF p. 80
Net cash generated from operating activitiesChinese yuan thousands 419,231895,895 PDF p. 80
Cash flows from investing activities
Additions to other financial assetsChinese yuan thousands (5,945,000)(1,160,963) PDF p. 80
Capital contribution into an associateChinese yuan thousands (31,707)(211,824) PDF p. 80
Capital distribution from an associateChinese yuan thousands 8,1825,280 PDF p. 80
Disposal of subsidiaries, net of cash disposedChinese yuan thousands –(347,800) PDF p. 80
Dividend income from associates and other financial assetsChinese yuan thousands 14,642354,168 PDF p. 80
Interest income receivedChinese yuan thousands 62,50031,200 PDF p. 80
Proceeds from disposal of property, plant and equipmentChinese yuan thousands 39179 PDF p. 80
Proceeds from disposal of land use rightsChinese yuan thousands 12,200– PDF p. 80
Proceeds from disposal of an associateChinese yuan thousands 1,623,4661,758,755 PDF p. 80
Proceeds from redemption of other financial assetsChinese yuan thousands 3,020,00060,000 PDF p. 80
Purchase of property, plant and equipment and intangible assetsChinese yuan thousands (130,813)(117,813) PDF p. 80
Net cash (used in)/generated from investing activitiesChinese yuan thousands (1,366,139)371,082 PDF p. 80
Definitions & sources

Consolidated cash flows — FY2025 source

12 metrics

Units appear below each metric. Scroll to compare years

Consolidated cash flows — FY2025 source from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2025Group2024Group Source
Cash flows from financing activities
Interest expense paidChinese yuan thousands (101)(28,375) PDF p. 81
Dividends paidChinese yuan thousands (981,185)(982,214) PDF p. 81
Dividends paid to non-controlling interestsChinese yuan thousands –(4,980) PDF p. 81
Proceeds from bank loansChinese yuan thousands 5,0001,221,071 PDF p. 81
Repayment of lease liabilitiesChinese yuan thousands (2,595)(5,103) PDF p. 81
Repayments of bank loansChinese yuan thousands (2,000)(520,005) PDF p. 81
Repurchase of restricted A-SharesChinese yuan thousands –(282) PDF p. 81
Net cash used in financing activitiesChinese yuan thousands (980,881)(319,888) PDF p. 81
Net (decrease)/increase in cash and cash equivalentsChinese yuan thousands (1,927,789)947,089 PDF p. 81
Cash and cash equivalents at beginning of the yearChinese yuan thousands 2,944,4331,997,386 PDF p. 81
Effect of foreign exchange rate changes on cash and cash equivalentsChinese yuan thousands (217)(42) PDF p. 81
Cash and cash equivalents at end of the yearChinese yuan thousands 1,016,4272,944,433 PDF p. 81
Definitions & sources

Group EPS calculation inputs — Note31

2 metrics

Units appear below each metric. Scroll to compare years

Group EPS calculation inputs — Note31 from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2025Group2024Group Source
Group EPS calculation inputs — Note31
Profit for the year attributable to owners of the CompanyChinese yuan thousands 2,131,0222,229,335 PDF p. 152
Weighted average number of ordinary sharesthousands of ordinary shares 770,094770,149 PDF p. 152
Definitions & sources

No potentially dilutive ordinary shares exist; basic and diluted EPS are the same. Shares are counts, not RMB amounts.

Original dividend rate columns — Note32

3 metrics

Units appear below each metric. Scroll to compare years

Original dividend rate columns — Note32 from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2025Group and Company — original Cents per share / RMB rate column2024Group and Company — original Cents per share / RMB rate column Source
Original dividend rate columns — Note32
Final dividends for the year endedPrinted header: Cents per share; RMB 1.281.28 PDF p. 153
Interim dividends for the year endedPrinted header: Cents per share; RMB 2.45– PDF p. 153
SubtotalPrinted header: Cents per share; RMB 3.731.28 PDF p. 153
Definitions & sources

Original rate header prints Cents per share and RMB while literal values are1.28/2.45/3.73. The contradictory/ambiguous rate-unit wording is retained without a conversion or inferred replacement. Separate cash columns explicitly useRMBthousands. Final paid relates toFY2024(comparativeFY2023); interim paid relates toFY2025.

Proposed final is explicitlyRMB23.4per10shares, approximatelyRMB1,802,020,793, proposed30March2026 and not recognised as a liability pending shareholder approval. The proposed amount and rate are distinct from current paid/declared amounts and financing cash dividends.

Dividends to owners — cash amounts Note32

3 metrics

Units appear below each metric. Scroll to compare years

Dividends to owners — cash amounts Note32 from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2025Group and Company — cash dividends RMBthousands2024Group and Company — cash dividends RMBthousands Source
Dividends to owners — cash amounts Note32
Final dividends for the year endedChinese yuan thousands 985,721985,803 PDF p. 153
Interim dividends for the year endedChinese yuan thousands 1,886,731– PDF p. 153
SubtotalChinese yuan thousands 2,872,452985,803 PDF p. 153
Definitions & sources

Original rate header prints Cents per share and RMB while literal values are1.28/2.45/3.73. The contradictory/ambiguous rate-unit wording is retained without a conversion or inferred replacement. Separate cash columns explicitly useRMBthousands. Final paid relates toFY2024(comparativeFY2023); interim paid relates toFY2025.

Proposed final is explicitlyRMB23.4per10shares, approximatelyRMB1,802,020,793, proposed30March2026 and not recognised as a liability pending shareholder approval. The proposed amount and rate are distinct from current paid/declared amounts and financing cash dividends.

Proposed final dividend — Note32

2 metrics

Units appear below each metric. Scroll to compare years

Proposed final dividend — Note32 from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2025Proposed final dividend forFY2025 —decision30March2026 Source
Proposed final dividend — Note32
proposed a final dividend amounting toChinese yuan 1,802,020,793 PDF p. 153
RMB23.4 for every 10 sharesChinese yuan per10shares 23.4 PDF p. 153
Definitions & sources

Original rate header prints Cents per share and RMB while literal values are1.28/2.45/3.73. The contradictory/ambiguous rate-unit wording is retained without a conversion or inferred replacement. Separate cash columns explicitly useRMBthousands. Final paid relates toFY2024(comparativeFY2023); interim paid relates toFY2025.

Proposed final is explicitlyRMB23.4per10shares, approximatelyRMB1,802,020,793, proposed30March2026 and not recognised as a liability pending shareholder approval. The proposed amount and rate are distinct from current paid/declared amounts and financing cash dividends.

Group equity CAS / IFRS reconciliation — FY2025

3 metrics

Units appear below each metric. Scroll to compare years

Group equity CAS / IFRS reconciliation — FY2025 from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2025Group — CAS statutory financial statements2025Group — Reconciliation to IFRS2025Group — IFRS financial statements Source
Equity
Share premiumChinese yuan thousands –1,206,9301,206,930 PDF p. 162
Retained earningsChinese yuan thousands 4,893,598108,7485,002,346 PDF p. 162
Other reservesChinese yuan thousands 1,435,807(1,315,678)120,129 PDF p. 162
Definitions & sources

Original Note37 reclassifications of retained earnings, share premium and other reserves. The report explicitly says no financial impact on total comprehensive income and net assets of Group/Company at the reporting date.

Group equity CAS / IFRS reconciliation — FY2024

3 metrics

Units appear below each metric. Scroll to compare years

Group equity CAS / IFRS reconciliation — FY2024 from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2024Group — CAS statutory financial statements2024Group — Reconciliation to IFRS2024Group — IFRS financial statements Source
Equity
Share premiumChinese yuan thousands –1,206,9301,206,930 PDF p. 162
Retained earningsChinese yuan thousands 5,635,028108,7485,743,776 PDF p. 162
Other reservesChinese yuan thousands 1,438,472(1,315,678)122,794 PDF p. 162
Definitions & sources

Original Note37 reclassifications of retained earnings, share premium and other reserves. The report explicitly says no financial impact on total comprehensive income and net assets of Group/Company at the reporting date.

Company equity CAS / IFRS reconciliation — FY2025

3 metrics

Units appear below each metric. Scroll to compare years

Company equity CAS / IFRS reconciliation — FY2025 from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2025Company — CAS statutory financial statements2025Company — Reconciliation to IFRS2025Company — IFRS financial statements Source
Equity
Share premiumChinese yuan thousands –1,206,9301,206,930 PDF p. 162
Retained earningsChinese yuan thousands 4,650,56631,0004,681,566 PDF p. 162
Other reservesChinese yuan thousands 1,772,708(1,237,930)534,778 PDF p. 162
Definitions & sources

Original Note37 reclassifications of retained earnings, share premium and other reserves. The report explicitly says no financial impact on total comprehensive income and net assets of Group/Company at the reporting date.

Company equity CAS / IFRS reconciliation — FY2024

3 metrics

Units appear below each metric. Scroll to compare years

Company equity CAS / IFRS reconciliation — FY2024 from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2024Company — CAS statutory financial statements2024Company — Reconciliation to IFRS2024Company — IFRS financial statements Source
Equity
Share premiumChinese yuan thousands –1,206,9301,206,930 PDF p. 162
Retained earningsChinese yuan thousands 5,500,35331,0005,531,353 PDF p. 162
Other reserveChinese yuan thousands 1,775,567(1,237,930)537,637 PDF p. 162
Definitions & sources

Original Note37 reclassifications of retained earnings, share premium and other reserves. The report explicitly says no financial impact on total comprehensive income and net assets of Group/Company at the reporting date.

Group / Company balance sheets — FY2023 source

39 metrics

Units appear below each metric. Scroll to compare years

Group / Company balance sheets — FY2023 source from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2023Group2022Group2023Company2022Company Source
Non-Current Assets
Property, plant and equipmentChinese yuan thousands 1,434,7421,461,594980,909987,931 PDF p. 79
Investment propertiesChinese yuan thousands 13,02914,09912,29913,321 PDF p. 79
Right-of-use assetsChinese yuan thousands 6,7692,994–– PDF p. 79
Land use rightsChinese yuan thousands 251,739204,021203,677152,096 PDF p. 79
Intangible assetsChinese yuan thousands 144,997172,80219,21617,257 PDF p. 79
SubsidiariesChinese yuan thousands ––1,652,4541,536,265 PDF p. 79
AssociatesChinese yuan thousands 882,307760,193882,307760,193 PDF p. 79
Deferred tax assetsChinese yuan thousands 265,993208,352232,063179,689 PDF p. 79
Other financial assetsChinese yuan thousands 622,81241,272560,873321 PDF p. 79
Other assetsChinese yuan thousands 56,03946,21051,29340,550 PDF p. 79
SubtotalChinese yuan thousands 3,678,4272,911,5374,595,0913,687,623 PDF p. 79
Current Assets
InventoriesChinese yuan thousands 1,566,5181,429,4521,123,625785,984 PDF p. 79
Trade and other receivablesChinese yuan thousands 2,686,9292,785,1172,042,0652,337,302 PDF p. 79
Other financial assetsChinese yuan thousands 61,69940,615–– PDF p. 79
Other assetsChinese yuan thousands 111,329107,73634,62314,377 PDF p. 79
Cash and cash equivalentsChinese yuan thousands 2,125,2002,882,5241,441,8712,075,925 PDF p. 79
SubtotalChinese yuan thousands 6,551,6757,245,4444,642,1845,213,588 PDF p. 79
Total assetsChinese yuan thousands 10,230,10210,156,9819,237,2758,901,211 PDF p. 79
EQUITY
Capital and Reserves Share capitalChinese yuan thousands 770,158773,443770,158773,443 PDF p. 79 Label p. 79
Share premiumChinese yuan thousands 1,207,3261,228,7401,207,3261,228,740 PDF p. 79
Retained earningsChinese yuan thousands 4,500,0204,372,4624,456,4604,275,060 PDF p. 79
Other reservesChinese yuan thousands 130,224176,564545,067559,241 PDF p. 79
Equity attributable to owners
Equity attributable to owners of the companyChinese yuan thousands 6,607,7286,551,2096,979,0116,836,484 PDF p. 79 Label p. 79
Non-controlling interestsChinese yuan thousands 44,54630,493–– PDF p. 79
Total equityChinese yuan thousands 6,652,2746,581,7026,979,0116,836,484 PDF p. 79
Non-Current Liabilities
Deferred tax liabilitiesChinese yuan thousands 7,3338,818–– PDF p. 79
Trade and other payablesChinese yuan thousands 8,14910,0915,7499,005 PDF p. 79
Lease liabilitiesChinese yuan thousands 2,743871–– PDF p. 79
Other financial liabilitiesChinese yuan thousands 241,035151,300241,035123,310 PDF p. 79
Other liabilitiesChinese yuan thousands 92,682100,51357,87955,379 PDF p. 79
SubtotalChinese yuan thousands 351,942271,593304,663187,694 PDF p. 79
Current Liabilities
Income tax payableChinese yuan thousands 76,67893,28052,37376,138 PDF p. 79
Trade and other payablesChinese yuan thousands 2,890,2842,885,4221,759,1151,516,835 PDF p. 79
Lease liabilitiesChinese yuan thousands 3,5644,097–– PDF p. 79
Other financial liabilitiesChinese yuan thousands 81,800101,639–80,531 PDF p. 79
Other liabilitiesChinese yuan thousands 173,560219,248142,113203,529 PDF p. 79
SubtotalChinese yuan thousands 3,225,8863,303,6861,953,6011,877,033 PDF p. 79
Total liabilitiesChinese yuan thousands 3,577,8283,575,2792,258,2642,064,727 PDF p. 79
Total equity and liabilitiesChinese yuan thousands 10,230,10210,156,9819,237,2758,901,211 PDF p. 79
Definitions & sources

Consolidated profit / comprehensive income — FY2023 source

25 metrics

Units appear below each metric. Scroll to compare years

Consolidated profit / comprehensive income — FY2023 source from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2023Group2022Group Source
Consolidated profit / comprehensive income — FY2023 source
RevenueChinese yuan thousands 8,222,3128,249,250 PDF p. 78
Cost of salesChinese yuan thousands (4,683,129)(5,032,282) PDF p. 78
Gross ProfitChinese yuan thousands 3,539,1833,216,968 PDF p. 78
Interest incomeChinese yuan thousands 54,64256,125 PDF p. 78
Dividend incomeChinese yuan thousands 100– PDF p. 78
Other income and gainsChinese yuan thousands 39,949102,385 PDF p. 78
Marketing and distribution expensesChinese yuan thousands (2,126,435)(1,969,265) PDF p. 78
Research and development expensesChinese yuan thousands (184,629)(153,147) PDF p. 78
Administrative expensesChinese yuan thousands (400,360)(388,355) PDF p. 78
Finance costsChinese yuan thousands (24,589)(13,158) PDF p. 78
Other lossesChinese yuan thousands (97,075)(67,977) PDF p. 78
Share of results of equity-accounted associates, net of taxChinese yuan thousands 294,577196,613 PDF p. 78
Profit before taxChinese yuan thousands 1,095,363980,189 PDF p. 78
Tax expenseChinese yuan thousands (126,658)(106,931) PDF p. 78
Profit for the yearChinese yuan thousands 968,705873,258 PDF p. 78
Items that will not be reclassified subsequently to profit or loss:
Change in fair value of equity investments at FVOCI, net of taxChinese yuan thousands 39(944) PDF p. 78
Share of other comprehensive income from equity-accounted associates, net of taxChinese yuan thousands 4,7676,995 PDF p. 78 Label p. 78
Other comprehensive income for the yearChinese yuan thousands 4,8066,051 PDF p. 78
Total comprehensive income for the yearChinese yuan thousands 973,511879,309 PDF p. 78
Profit for the year attributable to: Owners of the CompanyChinese yuan thousands 986,707861,794 PDF p. 78 Label p. 78
Non-controlling interestsChinese yuan thousands (18,002)11,464 PDF p. 78
Profit for the yearChinese yuan thousands 968,705873,258 PDF p. 78
Total comprehensive income attributable to:
Owners of the CompanyChinese yuan thousands 991,513867,845 PDF p. 78
Non-controlling interestsChinese yuan thousands (18,002)11,464 PDF p. 78
Total comprehensive income for the yearChinese yuan thousands 973,511879,309 PDF p. 78
Definitions & sources

Basic / diluted EPS — FY2023 source

1 metrics

Units appear below each metric. Scroll to compare years

Basic / diluted EPS — FY2023 source from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2023Group2022Group Source
Total comprehensive income attributable to:
Profit per share attributable to owners of the Company Basic and diluted (RMB per share)Chinese yuan per share 1.281.11 PDF p. 78 Label p. 78
Definitions & sources

Group equity movements — FY2023 source — ending2023

12 metrics

Units appear below each metric. Scroll to compare years

Group equity movements — FY2023 source — ending2023 from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2023Group — Share capital2023Group — Share premium2023Group — Other reserves2023Group — Retained earnings2023Group — Equity attributable to owners2023Group — Non-controlling interests2023Group — Total equity Source
Group equity movements — FY2023 source
At 1 January 2023Chinese yuan thousands 773,4431,228,740176,5644,372,4626,551,20930,4936,581,702 PDF p. 80
Profit for the yearChinese yuan thousands –––986,707986,707(18,002)968,705 PDF p. 80
Change in fair value of equity investments at FVOCI, net of taxChinese yuan thousands ––39–39–39 PDF p. 80 Label p. 80
Share of other comprehensive income from equity-accounted associates, net of taxChinese yuan thousands ––4,767–4,767–4,767 PDF p. 80 Label p. 80
Total other comprehensive incomeChinese yuan thousands ––4,806–4,806–4,806 PDF p. 80
Total comprehensive incomeChinese yuan thousands ––4,806986,707991,513(18,002)973,511 PDF p. 80
Contributions by and distributions to
Dividends (Note 32)Chinese yuan thousands –––(862,679)(862,679)–(862,679) PDF p. 80
Acquisition of non-controlling interest without change in control (Note 9(b)) and contribution from non-controlling interestsChinese yuan thousands ––(32,166)–(32,166)32,055(111) PDF p. 80 Label p. 80
Net reversal of share-based payments (Note 17)Chinese yuan thousands ––(18,980)–(18,980)–(18,980) PDF p. 80 Label p. 80
Repurchase and cancellation of Restricted A-SharesChinese yuan thousands (3,285)(21,414)–3,530(21,169)–(21,169) PDF p. 80 Label p. 80
Total transactions with ownersChinese yuan thousands (3,285)(21,414)(51,146)(859,149)(934,994)32,055(902,939) PDF p. 80
At 31 December 2023Chinese yuan thousands 770,1581,207,326130,2244,500,0206,607,72844,5466,652,274 PDF p. 80
Definitions & sources

Group equity movements — FY2023 source — ending2022

14 metrics

Units appear below each metric. Scroll to compare years

Group equity movements — FY2023 source — ending2022 from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2022Group — Share capital2022Group — Share premium2022Group — Other reserves2022Group — Retained earnings2022Group — Equity attributable to owners2022Group — Non-controlling interests2022Group — Total equity Source
Contributions by and distributions to
At 1 January 2022Chinese yuan thousands 773,4431,228,740504,0773,890,2506,396,510149,3526,545,862 PDF p. 80
Profit for the yearChinese yuan thousands –––861,794861,79411,464873,258 PDF p. 80
Change in fair value of equity investments at FVOCI, net of taxChinese yuan thousands ––(944)–(944)–(944) PDF p. 80 Label p. 80
Share of other comprehensive income from equity-accounted associates, net of taxChinese yuan thousands ––6,995–6,995–6,995 PDF p. 80 Label p. 80
Total other comprehensive incomeChinese yuan thousands ––6,051–6,051–6,051 PDF p. 80
Total comprehensive incomeChinese yuan thousands ––6,051861,794867,84511,464879,309 PDF p. 80
Dividends (Note 32)Chinese yuan thousands –––(386,721)(386,721)–(386,721) PDF p. 80
Distribution to non-controlling interests (Note 32)Chinese yuan thousands –––––(14,965)(14,965) PDF p. 80 Label p. 80
De-recognition of equity instruments at FVOCIChinese yuan thousands ––(7,139)7,139––– PDF p. 80 Label p. 80
Acquisition of non-controlling interests without change in control (Note 9(b))Chinese yuan thousands ––(323,976)–(323,976)(126,024)(450,000) PDF p. 80 Label p. 80
Acquisition of a subsidiary (Note 9(a))Chinese yuan thousands ––(9,274)–(9,274)10,6661,392 PDF p. 80
Share-based payments (Note 17)Chinese yuan thousands ––6,825–6,825–6,825 PDF p. 80
Total transactions with ownersChinese yuan thousands ––(333,564)(379,582)(713,146)(130,323)(843,469) PDF p. 80
At 31 December 2022Chinese yuan thousands 773,4431,228,740176,5644,372,4626,551,20930,4936,581,702 PDF p. 80
Definitions & sources

Company equity movements — FY2023 source — ending2023

10 metrics

Units appear below each metric. Scroll to compare years

Company equity movements — FY2023 source — ending2023 from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2023Company — Share capital2023Company — Share premium2023Company — Other reserves2023Company — Retained earnings2023Company — Total equity Source
Company equity movements — FY2023 source
At 1 January 2023Chinese yuan thousands 773,4431,228,740559,2414,275,0606,836,484 PDF p. 81
Profit for the yearChinese yuan thousands –––1,040,5491,040,549 PDF p. 81
Change in fair value of equity investments at FVOCI, net of taxChinese yuan thousands ––39–39 PDF p. 81 Label p. 81
Share of other comprehensive income from equity-accounted associates, net of taxChinese yuan thousands ––4,767–4,767 PDF p. 81 Label p. 81
Total comprehensive incomeChinese yuan thousands ––4,8061,040,5491,045,355 PDF p. 81
Contributions by and distributions
Dividends (Note 32)Chinese yuan thousands –––(862,679)(862,679) PDF p. 81
Net reversal of share-based payments (Note 17)Chinese yuan thousands ––(18,980)–(18,980) PDF p. 81 Label p. 81
Repurchase and cancellation of Restricted A-SharesChinese yuan thousands (3,285)(21,414)–3,530(21,169) PDF p. 81 Label p. 81
Total transactions with ownersChinese yuan thousands (3,285)(21,414)(18,980)(859,149)(902,828) PDF p. 81
At 31 December 2023Chinese yuan thousands 770,1581,207,326545,0674,456,4606,979,011 PDF p. 81
Definitions & sources

Company equity movements — FY2023 source — ending2022

10 metrics

Units appear below each metric. Scroll to compare years

Company equity movements — FY2023 source — ending2022 from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2022Company — Share capital2022Company — Share premium2022Company — Other reserves2022Company — Retained earnings2022Company — Total equity Source
Contributions by and distributions
At 1 January 2022Chinese yuan thousands 773,4431,228,740553,5043,818,8746,374,561 PDF p. 81
Profit for the yearChinese yuan thousands –––835,768835,768 PDF p. 81
Change in fair value of equity investments at FVOCI, net of taxChinese yuan thousands ––(944)–(944) PDF p. 81 Label p. 81
Share of other comprehensive income from equity-accounted associates, net of taxChinese yuan thousands ––6,995–6,995 PDF p. 81 Label p. 81
Total comprehensive incomeChinese yuan thousands ––6,051835,768841,819 PDF p. 81
Dividends (Note 32)Chinese yuan thousands –––(386,721)(386,721) PDF p. 81
De-recognition of equity instruments at FVOCIChinese yuan thousands ––(7,139)7,139– PDF p. 81 Label p. 81
Share-based payments (Note 17)Chinese yuan thousands ––6,825–6,825 PDF p. 81
Total transactions with ownersChinese yuan thousands ––(314)(379,582)(379,896) PDF p. 81
At 31 December 2022Chinese yuan thousands 773,4431,228,740559,2414,275,0606,836,484 PDF p. 81
Definitions & sources

Consolidated cash flows — FY2023 source

34 metrics

Units appear below each metric. Scroll to compare years

Consolidated cash flows — FY2023 source from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2023Group2022Group Source
Cash flows from operating activities
Profit before taxChinese yuan thousands 1,095,363980,188 PDF p. 82
Adjustments for:
Interest incomeChinese yuan thousands (54,642)(56,125) PDF p. 82
Interest expenseChinese yuan thousands 24,58913,158 PDF p. 82
Dividend incomeChinese yuan thousands (100)– PDF p. 82
Gain on re-measurement of fair value of previously-held equity interestsChinese yuan thousands –(72,010) PDF p. 82 Label p. 82
Investment income on debts instruments at amortised costChinese yuan thousands (13,430)(5,597) PDF p. 82
Share of results from equity-accounted associatesChinese yuan thousands (294,577)(196,613) PDF p. 82
Depreciation and amortisation of property, plant and equipment, investment property, right-of-use assets, land use rights, intangible assets and other non-current assetsChinese yuan thousands 133,154120,669 PDF p. 82 Label p. 82
Net losses/(gains) on disposal of property, plant and equipment and intangible assetsChinese yuan thousands 481(671) PDF p. 82 Label p. 82
Impairment of property, plant and equipmentChinese yuan thousands 24,951180 PDF p. 82
Write-down of inventories to net realisable valueChinese yuan thousands 28,13036,122 PDF p. 82
ECL allowance for trade and other receivablesChinese yuan thousands 23,2952,496 PDF p. 82
Impairment on goodwillChinese yuan thousands 18,78219,571 PDF p. 82
(Net reversal of share-based payments)/Share-based paymentsChinese yuan thousands (18,980)6,825 PDF p. 82
Operating profit before working capital changesChinese yuan thousands 967,016848,193 PDF p. 82
Changes in working capital:
– InventoriesChinese yuan thousands (165,338)58,873 PDF p. 82
– Trade and other receivablesChinese yuan thousands 90,456(737,508) PDF p. 82
– Other assetsChinese yuan thousands (16,448)5,216 PDF p. 82
– Trade and other payablesChinese yuan thousands (28,840)694,948 PDF p. 82
– Cash restricted in useChinese yuan thousands 43,177(170,991) PDF p. 82
– Other liabilitiesChinese yuan thousands (53,519)3,028 PDF p. 82
Cash generated from operationsChinese yuan thousands 836,504701,759 PDF p. 82
Tax paidChinese yuan thousands (202,658)(80,638) PDF p. 82
Net cash generated from operating activitiesChinese yuan thousands 633,846621,121 PDF p. 82
Cash flows from investing activities
Purchase of property, plant and equipment, intangible assets and land use rightsChinese yuan thousands (140,928)(107,902) PDF p. 82 Label p. 82
Proceeds from disposals of property, plant and equipment and intangible assetsChinese yuan thousands 1861,488 PDF p. 82 Label p. 82
Acquisition of a subsidiary, net of cash acquiredChinese yuan thousands –(47,611) PDF p. 82
Acquisition of additional equity interests in subsidiaryChinese yuan thousands –(450,000) PDF p. 82
Acquisition of other financial assetsChinese yuan thousands (630,000)(80,000) PDF p. 82
Deposit paid for acquisition of interests in an associateChinese yuan thousands (26,000)– PDF p. 82
Proceeds from disposals and redemption of other financial assetsChinese yuan thousands 49,649464,924 PDF p. 82
Interest income receivedChinese yuan thousands 55,49489,871 PDF p. 82
Dividend income from associates and other financial assets measured at FVOCIChinese yuan thousands 177,330173,075 PDF p. 82 Label p. 82
Net cash (used in)/generated from investing activitiesChinese yuan thousands (514,269)43,845 PDF p. 82
Definitions & sources

Consolidated cash flows — FY2023 source

13 metrics

Units appear below each metric. Scroll to compare years

Consolidated cash flows — FY2023 source from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2023Group2022Group Source
Cash flows from financing activities
Contribution from non-controlling interestsChinese yuan thousands 2,880– PDF p. 83
Proceeds from loans and borrowingsChinese yuan thousands 870,858205,645 PDF p. 83
Repayments of loans and borrowingsChinese yuan thousands (800,961)(35,935) PDF p. 83
Repurchase of Restricted A-SharesChinese yuan thousands (22,665)– PDF p. 83
Dividends paidChinese yuan thousands (857,117)(385,954) PDF p. 83
Distributions to non-controlling interestsChinese yuan thousands –(14,965) PDF p. 83
Interest expense paidChinese yuan thousands (20,208)(1,480) PDF p. 83
Repayment of lease liabilitiesChinese yuan thousands (6,556)(3,931) PDF p. 83
Net cash used in financing activitiesChinese yuan thousands (833,769)(236,620) PDF p. 83
Net (decrease)/increase in cash and cash equivalentsChinese yuan thousands (714,192)428,346 PDF p. 83
Cash and bank balances at beginning of yearChinese yuan thousands 2,711,5332,283,181 PDF p. 83
Effect of foreign exchange rate changes on cash and cash equivalentsChinese yuan thousands 456 PDF p. 83
Cash and cash equivalents at end of yearChinese yuan thousands 1,997,3862,711,533 PDF p. 83
Definitions & sources

Group equity movements — FY2022 source — ending2022

9 metrics

Units appear below each metric. Scroll to compare years

Group equity movements — FY2022 source — ending2022 from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2022Group — Share capital2022Group — Share premium2022Group — Retained earnings2022Group — Other reserves2022Group — Equity attributable to owners2022Group — Non-controlling interests2022Group — Total equity Source
Group equity movements — FY2022 source
At 1 January 2022Chinese yuan thousands 773,4431,228,7403,890,250504,0776,396,510149,3526,545,862 PDF p. 75
Total comprehensive income for the yearChinese yuan thousands ––861,7946,051867,84511,464879,309 PDF p. 75 Label p. 75
Dividends (note 11A)Chinese yuan thousands ––(386,721)–(386,721)–(386,721) PDF p. 75
Distributions to non-controlling interests (note 11B)Chinese yuan thousands –––––(14,965)(14,965) PDF p. 75 Label p. 75
De-recognition of equity instruments at FVTOCIChinese yuan thousands ––7,139(7,139)––– PDF p. 75 Label p. 75
Acquisition of non-controlling interests without change in control (note 17C)Chinese yuan thousands –––(323,976)(323,976)(126,024)(450,000) PDF p. 75 Label p. 75
Acquisition of subsidiary (note 17B)Chinese yuan thousands –––(9,274)(9,274)10,6661,392 PDF p. 75 Label p. 75
Share-based payments (note 25)Chinese yuan thousands –––6,8256,825–6,825 PDF p. 75
At 31 December 2022Chinese yuan thousands 773,4431,228,7404,372,462176,5646,551,20930,4936,581,702 PDF p. 75
Definitions & sources

The original FY2022 comparative Group share capital is773,443 at31December2021, while the original FY2021 closing Group table prints777,443. Both whole source versions are retained without replacement.

Group equity movements — FY2022 source — ending2021

7 metrics

Units appear below each metric. Scroll to compare years

Group equity movements — FY2022 source — ending2021 from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2021Group — Share capital2021Group — Share premium2021Group — Retained earnings2021Group — Other reserves2021Group — Equity attributable to owners2021Group — Non-controlling interests2021Group — Total equity Source
Group equity movements — FY2022 source
At 1 January 2021Chinese yuan thousands 773,6431,229,9803,353,080486,4915,843,194141,4845,984,678 PDF p. 75
Total comprehensive income for the yearChinese yuan thousands ––769,1437,434776,57717,734794,311 PDF p. 75 Label p. 75
Repurchase and cancellation of Restricted A-SharesChinese yuan thousands (200)(1,240)––(1,440)–(1,440) PDF p. 75 Label p. 75
Dividends (note 11A)Chinese yuan thousands ––(231,973)–(231,973)–(231,973) PDF p. 75
Distributions to non-controlling interests (note 11B)Chinese yuan thousands –––––(9,866)(9,866) PDF p. 75 Label p. 75
Share-based payments (note 25)Chinese yuan thousands –––10,15210,152–10,152 PDF p. 75
At 31 December 2021Chinese yuan thousands 773,4431,228,7403,890,250504,0776,396,510149,3526,545,862 PDF p. 75
Definitions & sources

The original FY2022 comparative Group share capital is773,443 at31December2021, while the original FY2021 closing Group table prints777,443. Both whole source versions are retained without replacement.

Group / Company balance sheets — FY2021 source

39 metrics

Units appear below each metric. Scroll to compare years

Group / Company balance sheets — FY2021 source from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2021Group2020Group2021Company2020Company Source
Non-current assets
Property, plant and equipmentChinese yuan thousands 1,483,2731,457,0531,047,8161,035,555 PDF p. 61
Investment propertiesChinese yuan thousands 15,17721,51214,34920,634 PDF p. 61
Right-of-use assetsChinese yuan thousands 3,0542,609–– PDF p. 61
Land use rightsChinese yuan thousands 182,638188,289156,907161,744 PDF p. 61
Intangible assetsChinese yuan thousands 20,27015,73418,56813,045 PDF p. 61
Investments in subsidiariesChinese yuan thousands ––535,525498,428 PDF p. 61
Investments in associatesChinese yuan thousands 729,660687,538729,660687,538 PDF p. 61
Other financial assetsChinese yuan thousands 11,081116,31111,0818,348 PDF p. 61
Deferred tax assetsChinese yuan thousands 154,605165,480140,059150,376 PDF p. 61
Other assetsChinese yuan thousands 42,33325,25940,06722,415 PDF p. 61
Total non-current assetsChinese yuan thousands 2,642,0912,679,7852,694,0322,598,083 PDF p. 61
Current assets
InventoriesChinese yuan thousands 1,525,0891,487,7151,391,9571,344,912 PDF p. 61
Trade and other receivablesChinese yuan thousands 2,011,3192,007,4261,941,9821,918,755 PDF p. 61
Other financial assetsChinese yuan thousands 484,464–374,829– PDF p. 61
Other assetsChinese yuan thousands 120,940121,127103,188104,942 PDF p. 61
Cash and cash equivalentsChinese yuan thousands 2,283,1811,987,3342,055,6831,791,009 PDF p. 61
Total current assetsChinese yuan thousands 6,424,9935,603,6025,867,6395,159,618 PDF p. 61
Total assetsChinese yuan thousands 9,067,0848,283,3878,561,6717,757,701 PDF p. 61
Equity
Share capitalChinese yuan thousands 773,443773,643773,443773,643 PDF p. 61
Share premiumChinese yuan thousands 1,228,7401,229,9801,228,7401,229,980 PDF p. 61
Retained earningsChinese yuan thousands 3,890,2503,353,0803,818,8743,278,987 PDF p. 61
Other reservesChinese yuan thousands 504,077486,491553,504536,706 PDF p. 61
Equity attributable to owners
Equity attributable to owners of the CompanyChinese yuan thousands 6,396,5105,843,1946,374,5615,819,316 PDF p. 61 Label p. 61
Non-controlling interestsChinese yuan thousands 149,352141,484–– PDF p. 61
Total equityChinese yuan thousands 6,545,8625,984,6786,374,5615,819,316 PDF p. 61
Non-current liabilities
Deferred tax liabilitiesChinese yuan thousands 4,2123,8024,2123,802 PDF p. 61
Trade payablesChinese yuan thousands 12,44530,65912,29730,507 PDF p. 61
Lease liabilitiesChinese yuan thousands 1,5721,710–– PDF p. 61
Other financial liabilitiesChinese yuan thousands –30,000–– PDF p. 61
Other liabilitiesChinese yuan thousands 101,124103,47166,75767,618 PDF p. 61
Total non-current liabilitiesChinese yuan thousands 119,353169,64283,266101,927 PDF p. 61
Current liabilities
Income tax payableChinese yuan thousands 9,53010,492–1,760 PDF p. 61
Trade and other payablesChinese yuan thousands 2,145,1331,870,9071,896,4561,598,324 PDF p. 61
Lease liabilitiesChinese yuan thousands 1,5971,000–– PDF p. 61
Other financial liabilitiesChinese yuan thousands 30,000––– PDF p. 61
Other liabilitiesChinese yuan thousands 215,609246,668207,388236,374 PDF p. 61
Total current liabilitiesChinese yuan thousands 2,401,8692,129,0672,103,8441,836,458 PDF p. 61
Total liabilitiesChinese yuan thousands 2,521,2222,298,7092,187,1101,938,385 PDF p. 61
Total equity and liabilitiesChinese yuan thousands 9,067,0848,283,3878,561,6717,757,701 PDF p. 61
Definitions & sources

Consolidated profit / comprehensive income — FY2021 source

25 metrics

Units appear below each metric. Scroll to compare years

Consolidated profit / comprehensive income — FY2021 source from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2021Group2020Group Source
Consolidated profit / comprehensive income — FY2021 source
RevenueChinese yuan thousands 6,907,5446,603,652 PDF p. 60
Cost of salesChinese yuan thousands (4,214,548)(4,086,048) PDF p. 60
Gross profitChinese yuan thousands 2,692,9962,517,604 PDF p. 60
Interest incomeChinese yuan thousands 50,48328,072 PDF p. 60
Dividend incomeChinese yuan thousands –1,447 PDF p. 60
Other income and gainsChinese yuan thousands 69,84467,439 PDF p. 60
Marketing and distribution expensesChinese yuan thousands (1,556,447)(1,457,878) PDF p. 60
Research and development expensesChinese yuan thousands (161,052)(149,202) PDF p. 60
Administrative expensesChinese yuan thousands (388,769)(358,552) PDF p. 60
Finance costsChinese yuan thousands (1,909)(2,509) PDF p. 60
Other lossesChinese yuan thousands (17,937)(29,007) PDF p. 60
Share of results from equity-accounted associatesChinese yuan thousands 185,597150,644 PDF p. 60
Profit before taxChinese yuan thousands 872,806768,058 PDF p. 60
Income tax expenseChinese yuan thousands (85,929)(88,396) PDF p. 60
Profit for the yearChinese yuan thousands 786,877679,662 PDF p. 60
Items that will not be reclassified to profit or loss
Fair value gain on equity investments measured at fair value through other comprehensive income, net of taxChinese yuan thousands 2,3235,756 PDF p. 60 Label p. 60
Share of other comprehensive income/(loss) from equity-accounted associates, net of taxChinese yuan thousands 5,111(26,313) PDF p. 60 Label p. 60
Total other comprehensive income/(loss) for the yearChinese yuan thousands 7,434(20,557) PDF p. 60
Total comprehensive income for the yearChinese yuan thousands 794,311659,105 PDF p. 60
Profit for the year attributable to: Owners of the CompanyChinese yuan thousands 769,143661,705 PDF p. 60 Label p. 60
Non-controlling interestsChinese yuan thousands 17,73417,957 PDF p. 60
SubtotalChinese yuan thousands 786,877679,662 PDF p. 60
Total comprehensive income for the year attributable to:
Owners of the CompanyChinese yuan thousands 776,577641,148 PDF p. 60
Non-controlling interestsChinese yuan thousands 17,73417,957 PDF p. 60
SubtotalChinese yuan thousands 794,311659,105 PDF p. 60
Definitions & sources

Basic / diluted EPS — FY2021 source

1 metrics

Units appear below each metric. Scroll to compare years

Basic / diluted EPS — FY2021 source from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2021Group2020Group Source
Earnings per share currency unit
Basic and dilutedChinese yuan per share 0.990.86 PDF p. 60
Definitions & sources

Group equity movements — FY2021 source — ending2021

7 metrics

Units appear below each metric. Scroll to compare years

Group equity movements — FY2021 source — ending2021 from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2021Group — Share capital2021Group — Share premium2021Group — Retained earnings2021Group — Other reserves2021Group — Equity attributable to owners2021Group — Non-controlling interests2021Group — Total equity Source
Group equity movements — FY2021 source
At 1 January 2021Chinese yuan thousands 773,6431,229,9803,353,080486,4915,843,194141,4845,984,678 PDF p. 62
Total comprehensive income for the yearChinese yuan thousands ––769,1437,434776,57717,734794,311 PDF p. 62 Label p. 62
Repurchase and cancellation of Restricted A-SharesChinese yuan thousands (200)(1,240)––(1,440)–(1,440) PDF p. 62 Label p. 62
Dividends (note 11A)Chinese yuan thousands ––(231,973)–(231,973)–(231,973) PDF p. 62
Distributions to non-controlling interests (note 11B)Chinese yuan thousands –––––(9,866)(9,866) PDF p. 62 Label p. 62
Share-based payments (note 25)Chinese yuan thousands –––10,15210,152–10,152 PDF p. 62
At 31 December 2021Chinese yuan thousands 777,4431,228,7403,890,250504,0776,396,510149,3526,545,862 PDF p. 62
Definitions & sources

Original Group closing share capital777,443 differs by4,000thousand RMB from its capital bridge, balance-sheet773,443 and whole FY2022 comparative773,443. The source value is retained without replacement.

Group equity movements — FY2021 source — ending2020

10 metrics

Units appear below each metric. Scroll to compare years

Group equity movements — FY2021 source — ending2020 from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025
Metric / unit 2020Group — Share capital2020Group — Share premium2020Group — Retained earnings2020Group — Other reserves2020Group — Equity attributable to owners2020Group — Non-controlling interests2020Group — Total equity Source
Group equity movements — FY2021 source
At 1 January 2020Chinese yuan thousands 768,8731,198,8172,881,174539,3105,388,174135,0325,523,206 PDF p. 62
Total comprehensive income for the yearChinese yuan thousands ––661,705(20,557)641,14817,957659,105 PDF p. 62 Label p. 62
Issuance of shares under Restricted A-Share Incentive SchemeChinese yuan thousands 4,87031,783––36,653–36,653 PDF p. 62 Label p. 62
Repurchase and cancellation of Restricted A-SharesChinese yuan thousands (100)(620)––(720)–(720) PDF p. 62 Label p. 62
Appropriation of statutory common reserve (note 26B)Chinese yuan thousands ––(420)420––– PDF p. 62 Label p. 62
Transfers from fair value reserve to retained earnings upon de-recognition of other financial assets measured at fair value through other comprehensive incomeChinese yuan thousands ––42,432(42,432)––– PDF p. 62 Label p. 62
Dividends (note 11A)Chinese yuan thousands ––(231,811)–(231,811)–(231,811) PDF p. 62
Distributions to non-controlling interests (note 11B)Chinese yuan thousands –––––(11,505)(11,505) PDF p. 62 Label p. 62
Share-based payments (note 25)Chinese yuan thousands –––9,7509,750–9,750 PDF p. 62
At 31 December 2020Chinese yuan thousands 773,6431,229,9803,353,080486,4915,843,194141,4845,984,678 PDF p. 62
Definitions & sources

Where the money comes from

Segment information

By business

Financial information by operating segments 4 lines
Financial information by operating segments — Group
Item / unit 2025Revenue (RMB'000)2025Cost of sales (RMB'000)2025Gross profit (RMB'000)2024Revenue (RMB'000)2024Cost of sales (RMB'000)2024Gross profit (RMB'000) Source
Chinese medicineRMB'000 4,461,170(963,855)3,497,3155,657,331(2,362,850)3,294,481 PDF p. 161
Western medicineRMB'000 89,939(47,147)42,7921,192,007(1,152,751)39,256 PDF p. 161
UnallocatedRMB'000 366,227(346,621)19,606457,398(346,220)111,178 PDF p. 161
TotalRMB'000 4,917,336(1,357,623)3,559,7137,306,736(3,861,821)3,444,915 PDF p. 161
Notes

Unlabelled total row printed beneath Unallocated. Segments: Chinese medicine and Western medicine; items outside are unallocated.

Other than the information disclosed, no reconciliation of segment profit or loss and assets and liabilities to the Group's is disclosed as these are unallocated.

No individual customer contributes more than 10% of revenue in 2025 and 2024.

The Group operates mainly in the PRC. As a result, segmental information by geographical areas is not meaningful. Non-current assets are mainly located in the PRC.

Unlabelled total row printed beneath Unallocated. Comparative year of the same note 36 table.

The Group operates mainly in the PRC; geographical segmental information is not meaningful.

Debt

Borrowings

Liquidity risk: contractual undiscounted maturity - Group

Liquidity risk: contractual undiscounted maturity - Group — Group
Item / unit 2025Less than 1 year, RMB'00020252 to 5 years, RMB'0002025Total, RMB'000 Source
Group 2025
Other financial liabilitiesRMB'000 58,058–58,058 PDF p. 157
Lease liabilitiesRMB'000 3,3405,2078,547 PDF p. 157
Notes

2024 Group comparatives: Other financial liabilities 22,103 / – / 22,103; Lease liabilities 2,726 / 5,297 / 8,023 (on same page).

Liquidity risk: contractual undiscounted maturity - Group

Liquidity risk: contractual undiscounted maturity - Group — Group
Item / unit 2025Less than 1 year, RMB'00020252 to 5 years, RMB'0002025Total, RMB'0002024Less than 1 year, RMB'00020242 to 5 years, RMB'0002024Total, RMB'000 Source
Group
Other financial liabilitiesRMB'000 58,058–58,05822,103–22,103 PDF p. 157
Lease liabilitiesRMB'000 3,3405,2078,5472,7265,2978,023 PDF p. 157
Notes

2024 Group comparatives: Other financial liabilities 22,103 / – / 22,103; Lease liabilities 2,726 / 5,297 / 8,023 (on same page).

Liquidity risk: contractual undiscounted maturity - Company 2025

Liquidity risk: contractual undiscounted maturity - Company 2025 — Company
Item / unit 2025Less than 1 year, RMB'00020252 to 5 years, RMB'0002025Total, RMB'000 Source
Company 2025
Other financial liabilitiesRMB'000 48,864–48,864 PDF p. 158
Lease liabilitiesRMB'000 1,2534811,734 PDF p. 158
Notes

Company 2024: Other financial liabilities 20,056 / – / 20,056; no lease liabilities line.

Borrowing notes 3 tables

Other financial liabilities (bank loans and bills payables)

Other financial liabilities (bank loans and bills payables)
Item / unit 2025Group, RMB'0002024Group, RMB'0002025Company, RMB'0002024Company, RMB'000 Source
Other financial liabilities
Bank loans (unsecured)RMB'000 5,0002,000–– PDF p. 145
Bills payablesRMB'000 52,90319,65348,86419,653 PDF p. 145
Total other financial liabilitiesRMB'000 57,90321,65348,86419,653 PDF p. 145
Notes

Total row has no printed label.

Terms and conditions of outstanding bank loans (unsecured)

Terms and conditions of outstanding bank loans (unsecured)
Item / unit 2025Group, RMB'0002024Group, RMB'0002025Company, RMB'0002024Company, RMB'000 Source
Unsecured loans; interest rate 2.70%, maturity 2025
Bank loansRMB'000 –2,000–– PDF p. 145
Unsecured loans; interest rate 3.00 – 3.20%, maturity 2026
Bank loansRMB'000 5,000––– PDF p. 145
Notes

Interest rate (%) and maturity year printed as columns: 2.70% maturing 2025; 3.00 – 3.20% maturing 2026. All loans unsecured; currency RMB.

Lease liabilities and undiscounted lease payments

Lease liabilities and undiscounted lease payments
Item / unit 2025Group, RMB'0002024Group, RMB'0002025Company, RMB'0002024Company, RMB'000 Source
Lease liabilities
Non-currentRMB'000 4,6585,603510– PDF p. 144
CurrentRMB'000 3,1251,3291,190– PDF p. 144
Undiscounted lease payments due
– Year 1RMB'000 3,3402,7261,253– PDF p. 144
– Year 2RMB'000 2,5681,914481– PDF p. 144
– Year 3RMB'000 1,7661,661–– PDF p. 144
– Year 4RMB'000 8731,590–– PDF p. 144
– Year 5RMB'000 –132–– PDF p. 144
Less: Unearned interest costRMB'000 (764)(1,091)(34)– PDF p. 144
Notes

Total lease liabilities 7,783 / 6,932 / 1,700 / – ; undiscounted total 8,547 / 8,023 / 1,734 / – (unlabelled total rows).

Leases typically run 2 to 3 years; lease liabilities are secured by the lessors' title to the leased assets.

Payout

Dividends & distributions

Dividend policy

ItemValuePeriod / scopeSource
Dividend Policy The Board considers that it is imperative to balance the Group’s needs with the need to encourage shareholder loyalty. Accordingly, taking into account various factors such as the Group’s cash flow and financial position, capital needs, and possible expansion plans, the Board will determine the frequency and appropriate amount of dividends to be declared in any financial year. Group PDF p. 57

Dividends declared and proposed

ItemValuePeriod / scopeSource
Final dividends for the year ended 31 December 2024 (2024: 31 December 2023) 1.28 cents per share Group and Company; final dividend for FY2024 paid in 2025; comparative column 2024 is final for FY2023 PDF p. 153
Interim dividends for the year ended 31 December 2025 2.45 cents per share Group and Company; 2025 PDF p. 153
Dividends to owners of the Company total 3.73 cents per share Group and Company; 2025 (comparative 2024: 1.28) PDF p. 153
Proposed final dividend FY2025 RMB23.4 for every 10 shares Company; proposed 30 March 2026 for year ended 31 December 2025 · As at 2026-03-30 PDF p. 153

Extracted from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025 and checked against the cited pages; see the original report for full context.

Auditor’s report

Audit & risk signals

Audit opinion

ItemValuePeriod / scopeSource
Auditor Foo Kon Tan LLP Group PDF p. 75
Engagement partner Chin Bo Wui Group PDF p. 75
Opinion give a true and fair view Group and Company PDF p. 72

Key audit matters

ItemValuePeriod / scopeSource
Net realisable value of inventories The assessment of net realisable value of inventories involves a significant degree of management’s judgement. Group PDF p. 72
Impairment of trade receivables The allowance for impairment of trade receivables is estimated by management through the application of judgement and use of subjective assumptions. Group PDF p. 73

Extracted from TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025 and checked against the cited pages; see the original report for full context.

How to read these figures

Group and parent company or bank figures are labelled separately. Parentheses indicate negative amounts; a dash and NA retain the report’s notation.

Comparative figures follow TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED — Annual Report 2025, including retrospective adjustments. Adjusted and reported earnings may have different definitions; refer to each statement’s notes.

Primary amounts are Chinese yuan (RMB) thousands, with EPS in RMB per share. The SGX USD trading counter does not change the reported financial currency. The report prints Group consolidated profit/comprehensive income and cash flows, Group/Company balance sheets and equity movements. Separate primary Company profit/comprehensive-income/cash-flow statements are not printed; Company comprehensive income/profit is retained in its equity movements.

The Note32 rate-unit header prints Cents per share / RMB for values1.28/2.45/3.73; the source ambiguity is recorded and no cent/yuan conversion is inferred. The proposal separately and explicitly states RMB23.4per10shares.

The original FY2022 Group equity table, including its comparative FY2021, is separately retained to corroborate the original FY2021 closing share-capital discrepancy.

OriginalFY2021 Group closing share capital777,443 has a4,000thousand-RMB component/bridge discrepancy. The corroborating FY2022 comparative773,443 is separately retained; source completeness does not imply every original printed figure reconciles.

These tables show the available extracted figures. The original annual report contains the full statements, notes and definitions.